Ers mis Rhagfyr y llynedd, mae Kalydeco®, Orkambi®a Symkevi®wedi bod ar gael i gleifion sydd â ffeibrosis systig yng Nghymru, ar ôl i GIG Cymru a Vertex Pharmaceuticals ddod i gytundeb mynediad masnachol. Heddiw (30th Mehefin), yn sgil y cyhoeddiad gan GIG Lloegr bod cytundeb wedi ei gyrraedd i sicrhau bod therapi triphlyg Vertex (elexacaftor, tezacaftor, ivacaftor) ar gael yn nes ymlaen eleni, rwy’n awyddus i roi’r wybodaeth ddiweddaraf am y sefyllfa yng Nghymru.
Since December last year, patients with Cystic Fibrosis in Wales have been able to access Kalydeco®, Orkambi®and Symkevi®as a result of a commercial access agreement reached between NHS Wales and Vertex Pharmaceuticals.  Today (30 June), in light of the announcement by NHS England that they have reached an agreement to make Vertex’s triple therapy (elexacaftor, tezacaftor, ivacaftor) available later this year, I wish to provide an update on the situation in Wales.